Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile


Chile evaluated use of the CoronaVac vaccine in its countrywide COVID-19 mass vaccination campaign, which began on 2 February 2021, using a prospective national cohort that included participants ages 16 and older who belonged to the national public health system. The evaluation attempted to estimate the effectiveness of the inactivated SARSCoV-2 vaccine in preventing COVID-19, hospitalizations, intensive care unit (ICU) admissions, and deaths resulting from the disease. The effectiveness of the vaccine was calculated with adjustments for individual demographic and clinical factors. The cohort included approximately 10.2 million individuals. 

Among people who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) in preventing COVID-19; 87.5% (95% CI, 86.7 to 88.2) in preventing hospitalizations; 90.3% (95% CI, 89.1 to 91.4) in preventing ICU admissions; and 86.3% (95% CI, 84.5 to 87.9) in preventing COVID-19-related deaths. The results suggest that the inactivated SARS-CoV-2 vaccine was effective in preventing COVID-19, including severe illness and death – a finding consistent with the results of phase 2 trials of the vaccine.

Source: Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med (2021) https://doi.org/10.1056/NEJMoa2107715

  • Share: